{"id":17426,"date":"2025-05-06T23:23:44","date_gmt":"2025-05-06T13:23:44","guid":{"rendered":"https:\/\/doseme-rx.com\/?p=17426"},"modified":"2025-05-06T23:39:23","modified_gmt":"2025-05-06T13:39:23","slug":"model-switch-suggestion-and-population-dosing-matrix","status":"publish","type":"post","link":"https:\/\/doseme-rx.com\/it\/news-media\/article\/model-switch-suggestion-and-population-dosing-matrix","title":{"rendered":"Empowering Precision: DoseMeRx Introduces Model-Switch Suggestion and Population Dosing for More Confident, Individualized Therapy"},"content":{"rendered":"\n

Personalized Pharmacokinetic Models Provide Greater Therapy Confidence<\/em><\/p>\n\n\n\n

Jupiter, FL \u2013 May 6, 2025<\/p>\n\n\n\n

DoseMe, a leading provider of Bayesian model-informed precision dosing (MIPD), today announced new features for its DoseMeRx platform: Model-Switch Suggestion and Population Dosing Matrix. These tools enhance clinical confidence and accelerate accurate therapy decisions, especially for drugs requiring narrow therapeutic window precision like vancomycin, busulfan, tacrolimus, and warfarin.<\/p>\n\n\n\n

Model-Switch Suggestion<\/strong> empowers clinicians to identify alternative pharmacokinetic models that better align with evolving patient data, automatically analyzing model fit. This dynamic tool supplements clinical judgment with real-time data to support more personalized dosing.<\/p>\n\n\n\n

Population Dosing Matrix<\/strong> provides actionable insights even before the first drug level is drawn. Using robust population models, it previews potential, initial dosing regimens and predicted AUC24 outcomes, ensuring clinicians can begin therapy with greater clarity and precision.<\/p>\n\n\n\n

\u201cThese enhancements reinforce our commitment to smarter, safer therapy,\u201d said John Hardesky<\/a>, Chief Commercial Officer at DoseMe. \u201cBy streamlining dosing decisions with real-time intelligence, clinicians can spend more time focused on patient care, not manual calculations.\u201d<\/p>\n\n\n\n

Unlike the initial model selection based solely on demographics, Model-Switch Suggestion continuously monitors model performance, working alongside the existing Model Fit Indicator to refine recommendations over time. Institutions may also enable an optional, auditable auto-learning mode for greater flexibility under strict clinical oversight.<\/p>\n\n\n\n

\u201cThe promise of precision dosing is personalization without complexity,\u201d added Paul Edwards<\/a>, CEO of DoseMe. \u201cOur new features bring transparency and intelligence to the forefront, driving safer, more effective drug therapy.\u201d<\/p>\n\n\n\n

Key Benefits:<\/h3>\n\n\n\n